 |
The Journal of Neuroscience, November 23, 2005, 25(47):10874-10883; doi:10.1523/JNEUROSCI.2350-05.2005
 Previous Article | Next Article 
Neurobiology of Disease
Energy Inhibition Elevates  -Secretase Levels and Activity and Is Potentially Amyloidogenic in APP Transgenic Mice: Possible Early Events in Alzheimer's Disease Pathogenesis
Rodney A. Velliquette,1,2
Tracy O'Connor,1 and
Robert Vassar1,2
1Department of Cell and Molecular Biology and 2Center for Drug Discovery and Chemical Biology, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611
 -Secretase [-site amyloid precursor protein-cleaving enzyme 1 (BACE1)] is the key rate-limiting enzyme for the production of the -amyloid (A) peptide involved in the pathogenesis of Alzheimer's disease (AD). BACE1 levels and activity are increased in AD brain and are likely to drive A overproduction, but the cause of BACE1 elevation in AD is unknown. Interestingly, cerebral glucose metabolism and blood flow are both reduced in preclinical AD, suggesting that impaired energy production may be an early pathologic event in AD. To determine whether reduced energy metabolism would cause BACE1 elevation, we used pharmacological agents (insulin, 2-deoxyglucose, 3-nitropropionic acid, and kainic acid) to induce acute energy inhibition in C57/B6 wild-type and amyloid precursor protein (APP) transgenic (Tg2576) mice. Four hours after treatment, we observed that reduced energy production caused a  150% increase of cerebral BACE1 levels compared with control. Although this was a modest increase, the effect was long-lasting, because levels of the BACE1 enzyme remained elevated for at least 7 d after a single dose of energy inhibitor. In Tg2576 mice, levels of the BACE1-cleaved APP ectodomain APPs were also elevated and paralleled the BACE1 increase in both relative amount and duration. Importantly, cerebral A40 levels in Tg2576 were increased to 200% of control at 7 d after injection, demonstrating that energy inhibition was potentially amyloidogenic. These results support the hypothesis that impaired energy production in the brain may drive AD pathogenesis by elevating BACE1 levels and activity, which, in turn, lead to A overproduction. This process may represent one of the earliest pathogenic events in AD.
Key words: Alzheimer's disease pathogenesis; -secretase; BACE1; -amyloid peptide; APP transgenic mice; energy metabolism
Received June 8, 2005;
revised August 23, 2005;
accepted October 7, 2005.
This article has been cited by other articles:
|
|
|
|
 
G. R Seabrook, W. J. Ray, M. Shearman, and M. Hutton
BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics
Mol. Interv.,
October 1, 2007;
7(5):
261 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mihailovich, R. Thermann, F. Grohovaz, M. W. Hentze, and D. Zacchetti
Complex translational regulation of BACE1 involves upstream AUGs and stimulatory elements within the 5' untranslated region
Nucleic Acids Res.,
May 14, 2007;
35(9):
2975 - 2985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhao, Y. Fu, M. Yasvoina, P. Shao, B. Hitt, T. O'Connor, S. Logan, E. Maus, M. Citron, R. Berry, et al.
{beta}-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis
J. Neurosci.,
April 4, 2007;
27(14):
3639 - 3649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
